“The technology platform and intellectual property acquired from FILT may prove valuable for our continued endeavors to further develop innovative products to measure airway inflammation”
Aerocrine AB (STO:AEROB) today announced the acquisition of key assets related to the measurement of FENO from German company FILT Lungen & Thoraxdiagnostik GmbH. FILT and Aerocrine will collaborate to develop new applications for airway inflammation monitoring and FILT will cease further commercialization of the NO VARIO® product.
Over many years, Aerocrine has made very significant technological, clinical and commercial investments to develop the market for its inventions to measure airway inflammation in asthma and other respiratory disorders. Today, Aerocrine is the only company supplying quality-assured products for FENO monitoring approved by major regulatory authorities, including the FDA and SFDA, across the world. The company continues to invest in clinical trials and technology development for the benefit of care providers and people living with asthma.
"The technology platform and intellectual property acquired from FILT may prove valuable for our continued endeavors to further develop innovative products to measure airway inflammation", says Paul de Potocki, CEO of Aerocrine. "We look forward to working together with FILT and its General Manager, Mr. Rüdiger Eichler, who brings considerable technical expertise in the field."
"It requires significant resources to develop the technology and the international clinical documentation for products used in a major therapeutic area such as asthma. Aerocrine is the market leader and the ideal partner for FILT related to airway inflammation monitoring," says Mr. Eichler.
Following the consummation of the agreements, Aerocrine will cause appropriate papers to be filed in the Regional Court of Düsseldorf to withdraw its pending claims of patent infringement against FILT.
Precision in every drop: Inside Hamilton’s syringe technology